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Background: Aggressive breast cancer is a term commonly used in literature to describe breast cancer
with a poor prognosis. Identifying and understanding the factors associated with aggressiveness could be
helpful to the management of patients with breast cancer. Breast cancer is a heterogeneous disease, both
clinically and biologically, which may be responsible for the wide range of survival durations for patients
with metastatic disease.
Aim: The goal of this study was to identify the factors most often described in association with aggressive
metastatic breast cancer (MBC).
Methods: A systematic review was performed by querying PubMed from January 1, 2012 to June 1, 2014
for “metastatic breast cancer” (“aggressive” or “poor prognosis” or “high risk”). The level of evidence to
support each potential prognostic factor of aggressive MBC was also reviewed.
Results: The identiﬁed factors were grouped into 3 principle categories: clinical, biological, and patient
related. Because patient-related factors may not be indicative of inherent cancer aggressiveness, this
review focused only on clinical and biological factors. The factors with the highest levels of evidence to
support associations with survival in metastatic breast cancer were visceral metastases, number of
metastatic sites, disease-free interval, presence of CTCs, triple-negative disease, and tumour grade.
Conclusion: Identiﬁcation of these factors and understanding their contribution to the aggressiveness of
MBC and disease progression may lead to more personalized treatment in this patient population.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast cancer is the most prevalent cancer malignancy and the
leading cause of cancer-related mortality in women in developed
countries [1]. In 2014 in the United States, an estimated 232,670
women will be diagnosed with invasive breast cancer, and
40,000 will die from it [2]. In 2012 in Europe, there were an
estimated 463,800 new breast cancer cases and 131,200
breast cancererelated deaths [3]. Approximately 5% of patients
with breast cancer in the United States are diagnosed with
metastatic disease at initial presentation [4]. Furthermore, a
recent study found that approximately 10% of patients diagnosed
with early-stage breast cancer developed metastatic disease
within a mean follow-up of 5.7 years [5].
Breast cancer is a clinically and biologically heterogeneous dis-
ease, characterized by dysregulation of multiple cellular pathwaysClinica e Chirugia, Universita
Via S. Pansini 5, 80131 Napoli,
63.
.
Ltd. This is an open access article u[6] and different sensitivities to treatment [7e9], which may
contribute to the wide range of survival durations for patients with
metastatic disease. Some types of breast cancers are more aggres-
sive than others. “Aggressive breast cancer” is not a standard term
commonly used in the breast cancer literature. However, the ability
to identify factors associated with aggressive breast cancer and to
predict prognosis and treatment response has a considerable
impact on patient management.
Studies in early-stage breast cancer have established numerous
factors prognostic of efﬁcacy outcomes, including axillary nodal
status, tumour size, oestrogen receptor status, and histological
grade, among others [10,11]. There have been relatively fewer re-
ports on prognostic factors in metastatic breast cancer (MBC). This
may in part be due to the inherent difﬁculty in separating whether
a factor is a “pure” prognostic factor, a predictive factor for response
to therapy, or both. However, prognostic factors could aid in
selecting treatment for the individual patient and developing risk-
adjusted treatment strategies.
Here we report a systematic literature review of breast cancer
publications to identify potential prognostic factors of aggressive
MBC and describe studies that evaluated them.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Identifying factors
PubMedwas queried from January 1, 2012 to June 1, 2014 for the
following search terms: “metastatic breast cancer” (“aggressive” or
“poor prognosis” or “high risk”). The abstracts of the resulting
returns were reviewed for factors that were examined with respect
to prognosis, and these factors were chosen for more detailed
evaluation.
Evaluating factors
Once aggressive disease factors were identiﬁed, PubMed was
queried for each term speciﬁcally (“breast cancer” [prognostic OR
predictive] [speciﬁc factor]), with no date ranges selected to allow a
more robust analysis. If these criteria returned limited results for a
given factor, then the search was further relaxed. In selecting
studies to describe for the evaluation of factors, preference was
given to prospective, randomized data in evaluating the prognostic
ability of each factor. However, in many cases, retrospective ana-
lyses were the only studies available. Discussions were prioritized
to include the most relevant, statistically rigorous (prospective and
multivariate analysis where possible), and recent results possible.
Results of systematic analysis
Identiﬁcation of factors
The most relevant prognostic factors associated with aggressive
MBC were identiﬁed based on systematic search methods
described earlier. This search returned a total of 141 results (135 in
English). Three categories of factors were identiﬁed: clinical, bio-
logical, and patient-related (Table 1). Patient-related factors were
not examined in detail. Other factors were excluded for further
analysis for the following reasons: representation in only 1 report,Table 1
Identiﬁcation of potential prognostic factors for aggressive breast cancer.




Site of metastasis Yes Yes
Number of metastatic sites Yes Yes
DFI Yes Yes
Prior therapy Yes Yes
Nodal status Yes No
Response to prior therapy No Yes
Platelet-to-lymphocyte ratio No Yes
Biological
ER/PR status Yes Yes
HER2 status Yes Yes
TNBC Yes Yes
Presence of CTCs Yes Yes
Tumour grade/differentiation Yes Yes
Tumour size Yes Yes
Molecular subtype Yes Yes
Inﬂammation Yes Yes
Ki-67 No Yes
Histology (ductal vs lobular) No Yes
Concordance of receptor status between




Performance status Yes Yes
Race Yes Yes
CTCs, circulating tumour cells; DFI, disease-free interval; ER, oestrogen receptor; HER2
progesterone receptor; TNBC, triple-negative breast cancer.relevance to early-stage breast cancer only, or difﬁculty evaluating
the factor in other reports due to lack of uniformity in its deﬁnition.
Clinical features
Site of metastasis/recurrence
Deﬁnitions of metastatic sitemay vary slightly from one study to
the next. It may refer to simply the presence of a lesion in that site,
the ﬁrst distant recurrence after treatment for early-stage disease,
or the dominant site of metastasis.
Visceral metastases. Visceral lesions are those conﬁned to visceral
organs, typically the liver or lung. Approximately 70% of patients
enrolled in MBC trials have visceral metastases at baseline [12e14].
Multiple studies have suggested that the presence of visceral me-
tastases is associated with worse overall survival [15e20]. A phase
III trial (N ¼ 739) in which patients with MBC were treated with
doxorubicin, paclitaxel, or the combination of both demonstrated
that patients with visceral-dominant metastases had worse overall
survival than those with other dominant sites of metastasis [21].
Speciﬁcally, a multivariate analysis demonstrated that visceral-
dominant metastases were signiﬁcant, independent predictors of
overall survival (hazard ratio [HR] 1.4; P ¼ 0.004; Table 2). In
another robust dataset, a meta-analysis (N ¼ 1361) performed on
10 consecutive MBC trials conducted by the Hellenic Oncology
Cooperative Group (HeCOG) from 1991 through 2006 found that
the presence of visceral metastases signiﬁcantly associated with a
worse prognosis [17]. Most patients (79.5%) received taxanes as
ﬁrst-line treatment. Patients with visceral metastases made up 70%
of the total population. The results of a Cox model that accounted
for different treatments demonstrated a 44% higher risk of mor-
tality for patients with visceral metastases vs those without (HR
1.44; 95% CI, 1.24e1.68; P < 0.001; Table 2).
Brain metastases. Based on case series, the incidence of clinically




No e less relevant to understand disease aggressiveness
No e less relevant to MBC
No e low representation







No e focus will be on clinical markers (e.g., ER/PR, HER2)
No e no standard marker of inﬂammation in these reports
No e low representation
No e low representation
No e low representation
No e less relevant to understand disease aggressiveness
, human epidermal growth factor receptor-2; MBC, metastatic breast cancer; PR,
Table 2
Clinical factors associated with increased risk of death in patients with MBC.
Factor Level of evidence N HR (95% CI) P Value
Visceral metastasis (yes vs no)
Sledge et al. [21] Phase III trial e MVA 738 1.4 (NR) 0.004
Dafni et al. [17] Meta-analysis of phase II and III trials e MVA 1361 1.44 (1.24e1.68) <0.001
Brain metastasis (yes vs no)
Jung et al. [25] Retrospective review of a patient series e MVA 557 1.58 (1.04e2.41) 0.033
Largillier et al. [26] Retrospective review of a patient series e MVA 1038 15.00 (8.17e27.50) <0.0001
Number of metastatic sites
Fountzilas et al. [28]
(2 vs 1) Phase III trial e MVA 416 1.51 (1.03e2.21) 0.03
(3 vs 1) 2.47 (1.68e3.63) <0.001
Pierga et al. [27]
(2 vs 1) Retrospective review of multiple clinical trials e MVA 1430 1.22 (1.12e1.33) Overall 0.000001
(3 vs 1) 1.49 (1.25e1.77)
DFI
Yamamoto [33] (24 vs <24 months) Phase III trial e MVA 233 2.70 (1.92e3.79) <0.0001
Chang [19] (12 vs <12 months) Retrospective review of a patient series e MVA 346 1.59 (1.14e1.67) 0.0008
DFI, disease-free interval; HR, hazard ratio; MVA, multivariate analysis; NR, not reported.
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brain metastases have been found in up to 30% of patients [23].
Brain metastases occur slightly more frequently in patients with
human epidermal growth factor receptor-2epositive (HER2þ)
breast cancer than other molecular subtypes (14% vs 2%e11% in 1
study of 3726 patients) [24]. In a retrospective review that analysed
the records of >500 patients with MBC treated at a single centre,
the presence of brainmetastases was signiﬁcantly associatedwith a
shorter OS than the absence of brain metastases (HR 1.58; 95% CI,
1.04e2.41; P ¼ 0.033; Table 2) [25]. Similar ﬁndings were observed
in a separate retrospective analysis of >1000 patients [26]. The risk
of mortality was 15-fold higher for patients with brain metastases,
making metastasis to the brain the most powerful predictor of
survival in that study (Table 2).
Number of metastatic sites
Metastatic breast cancer trials often deﬁne groups of patients
based on the number of metastatic sites, generally setting thresh-
olds between 1 and 3 [14,27e30]. Higher numbers of metastatic
sites have generally indicated a worse prognosis for patients than
lower numbers of metastatic sites. For example, a phase III trial
(N ¼ 416) of patients treated with paclitaxel plus carboplatin,
docetaxel plus gemcitabine, or paclitaxel monotherapy (plus tras-
tuzumab in all patients with HER2þ disease) demonstrated that the
presence of >1 metastatic site (separate analyses of 2 vs 1 or 3 vs
1) was a signiﬁcant independent predictor of survival (Table 2) [28].
The presence of multiple metastatic sites was also conﬁrmed as a
factor associated with aggressive MBC in a retrospective review of
>1400 patients treated in 8 consecutive prospective trials of
anthracycline-based therapy for ﬁrst-line treatment at the Curie
Institute. The HR for 2 sites vs 1 site was 1.22, and the HR for 3
sites vs 1 site was 1.49 (overall P ¼ 0.000001; Table 2) [28].
Short disease-free interval
Multiple studies have shown that early recurrence is an inde-
pendent predictor of survival and that disease-free interval (DFI) is
one of the strongest prognostic factors reﬂecting the aggressiveness
of advanced breast cancer [19,31e33]. Researchers often group
patients based on DFI cutoffs of either 12 or 24 months
[14,19,27,33,34]. A study of patients treated in a phase III trial with
either tamoxifen or medroxyprogesterone acetate combined with
doxorubicin and cyclophosphamide found that patients with a DFI
<24 months had a better survival prognosis than those with a DFI
24 months (HR 2.70; 95% CI, 1.92e3.79; P < 0.0001; Table 2) [33].
More recently, Chang et al. demonstrated an association betweenshort DFI (<12 months) and a worse outcome in a series of patients
(N ¼ 346) identiﬁed retrospectively from a central laboratory [19].
The risk of mortality for patients with a shorter DFI was almost 60%
higher than the mortality risk of patients with a longer DFI
(Table 2).
Biological features
Histological and molecular subtypes
One of the most established factors upon which to base treat-
ment decisions is histological subtype. In general, breast cancer can
be divided into one of the following 3 subtypes based on the
expression of the hormone receptors (oestrogen and progesterone)
and HER2: hormone receptorepositive (59%e79%), HER2-
overexpressing (22%e24%), and triple-negative (13%e24%)
[35e38]. Differential gene expression proﬁles have also been used
to classify breast cancer into molecular subtypes with distinct bi-
ologies [39]. Speciﬁcally, 5 core molecular subtypes have been
identiﬁed: luminal A, luminal B, HER2-enriched, basal-like, and
normal-like [40]. The basal-like and HER2-enriched subtypes were
associated with the poorest outcomes [40]; however, a growing
number of HER2-targeted therapies has improved the prognosis of
patients with HER2-enriched disease [29,41,42]. Histological and
molecular subtypes show some degree of overlap. For example, the
majority of luminal A and luminal B tumours are hormone recep-
torepositive; nuclear staining of the proliferation marker protein
Ki-67 can distinguish between the 2 subtypes (<14% of cells in
luminal A and 14% of cells in luminal B) [6,37,43]. In addition, the
majority of molecularly deﬁned HER2-enriched disease is HER2þ in
the histological classiﬁcation [6,37]. Lastly, most basal-like tumours
are histologically triple negative [6,37]. Some might question the
degree of actionable detail that a molecular approach can provide
beyond classic histological subtyping based on these data. Others
might point to the incomplete overlap of subtypes as a clear indi-
cation of an opportunity to improve care.
Current treatment decisions are still based largely on histolog-
ical ﬁndings so we will focus on exploring the aggressiveness of
these subtypes [44]. However, trial inclusion criteria typically
specify patient populations based on the expression of hormone
receptors and HER2; therefore, comparisons between such sub-
types are not available in the context of current randomized clinical
trials.
HER2. HER2þ tumours are known to possess a number of factors
associated with an aggressive disease phenotype, including lymph
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frequent mutations in the gene TP53 [6,35]. In a seminal study
(N ¼ 86) of patients with early-stage breast cancer, ampliﬁcation of
the HER2/neu gene was signiﬁcantly associated with both time to
disease relapse (P ¼ 0.001) and overall survival (P ¼ 0.02) in
multivariate analyses [45]. Since that study, a number of HER2-
targeted therapies have been introduced that have improved efﬁ-
cacy outcomes for patients with HER2þ MBC, including trastuzu-
mab, lapatinib, pertuzumab, and trastuzumab emtansine
[29,41,42,46]; therefore, patients with HER2þ tumours are no
longer considered to have a worse prognosis than those with
HER2 tumours.Triple-negative breast cancer (TNBC). Like HER2þ tumours, triple-
negative tumours are also known to have an inherently aggres-
sive disease phenotype, including worse nuclear grade, worse
histological grade, high mitotic index, high genomic instability, and
mutations or loss of the genes TP53, PIK3CA, PTEN, RB1, and BRCA1
[6,35]. A large study of >50,000 patients from 8 regional registries
in California found that the 5-year survival rates for patients with
TNBC vs non-TNBC were 77% vs 93%, respectively [38]. The poor
prognosis of patients with TNBC was also conﬁrmed in a large trial
of patients with MBC treated with ﬁrst-line chemotherapy. In that
study, a multivariate analysis demonstrated a 4.3-folder higher risk
of mortality for patients with TNBC vs non-TNBC (Table 3) [47].
Unlike the hormone receptorepositive and HER2þ subtypes, no
targeted agents have yet been proven useful for triple-negative
disease.Circulating tumour cells (CTCs) as prognostic and predictive markers
Circulating tumour cells (CTCs) are tumour cells detectable in
blood that have been released by primary tumours or metastases
[48,49]. Counting and characterizing CTCs represent a relatively
recent approach to prognosis and determining response to therapy
[47,49e52]. Multiple prospective studies in breast cancer patients
have validated the prognostic signiﬁcance of baseline CTC level on
survival, and most use a cutoff of 5 CTCs per 7.5 mL of blood at
baseline to deﬁne prognostic groups [47,49,53].
In a randomized, prospective multicentre study on patients
(N ¼ 177) with MBC, Cristofanilli et al. found that the CTC level, as
measured before a new therapy was initiated and at the ﬁrst
follow-up visit, was a predictor of both progression-free survival
and overall survival [53]. In a multivariate analysis, a CTC count 5Table 3
Biological factors associated with increased risk of death in patients with MBC.
Factor Level of evidence
Histological status
HER2 (ampliﬁed vs not)
Slamon et al. [45] Retrospective review of a patient series e MVA
TNBC (yes vs no)
Pierga et al. [47] Prospective, multicentre study e MVA
Presence of CTCs (≥5 vs <5 per 7.5 mL)
Cristofanilli et al. [53] Prospective, multicentre study e MVA
Pierga et al. [47] Prospective, multicentre study e MVA
Wallwiener et al. [49] Prospective, multicentre study e MVA
Tumour grade
Poikonen et al. [57]
Grade 3 vs 2 or 1 Phase III trial e MVA
Largillier et al. [26]
Grade 2 or 3 vs 1 Retrospective review of a patient series e MVA
Primary tumour size
Largillier et al. [26]
>20 vs 20 mm Retrospective review of a patient series e MVA
CTCs, circulating tumour cells; HER2, human epidermal growth factor receptor-2; HR, haz
cancer.per 7.5 mL of blood was a signiﬁcant independent predictor of
worse survival compared with a CTC count <5 (HR 4.26; P < 0.001;
Table 3). A subgroup analysis of 83 patients who were treated with
ﬁrst-line chemotherapy conﬁrmed the prognostic signiﬁcance of
5 vs<5 CTCs per 7.5 mL of blood at baseline (multivariate HR 3.45;
P ¼ 0.01) [54]. Interestingly, the same study found that CTC level at
the ﬁrst follow-up visit was also predictive of progression-free and
overall survival [53].
Two more-recent prospective studies have conﬁrmed the
prognostic signiﬁcance of CTCs. The ﬁrst was an analysis of data
from 267 patients who received ﬁrst-line chemotherapy (±a tar-
geted agent, including trastuzumab or lapatinib for HER2þ disease
or bevacizumab for HER2 disease), which showed a >2-fold
higher probability of mortality for patients with 5 CTCs per
7.5 mL of blood at baseline (Table 3) [47]. The second analysis
included 468 patients with MBC who were initiating a new line of
systemic therapy [49]. The HR for survival in patients with5 vs <5
CTCs per 7.5 mL of blood at baseline in that study was almost 5
(Table 3).Tumour grade
Tumour grade, a measure of the differentiation and mitotic ac-
tivity of tumours, is a well-accepted prognostic marker in early-
stage breast cancer [44,55]. However, studies have revealed that
tumour grade is also associated with survival in MBC [26,56]. A
subanalysis of a phase III trial in which patients received either
methotrexate plus 5-ﬂuorouracil or docetaxel as second-line ther-
apy demonstrated a signiﬁcant association in multivariate analysis
between histological grade and overall survival [57]. Ninety-six
patients had evaluable immunohistochemical samples, and the
HR for grade 3 vs grade 1 or 2 was 1.95 (Table 3); although the P
value was not reported, the 95% CI did not cross 1, suggesting a
signiﬁcant difference. Histological grade was also a signiﬁcant, in-
dependent predictor of survival in a retrospective review of >1000
women with MBC treated at a single centre (multivariate HR 1.25;
95% CI, 1.00e1.55; P ¼ 0.048; Table 3) [26].Tumour size
Although tumour size is a component of tumour stage [44], only
tumour size was identiﬁed during the systematic search of poten-
tial prognostic factors associated with aggressive MBC. Like tumour
grade, primary tumour size may be thought of more as a prognostic
factor for early-stage disease. However, a study of 1038 patientsN HR (95% CI) P value
83 NR 0.02
1430 4.3 (2.1e8.8) 0.0002
177 4.26 (NR) <0.001
267 2.4 (1.1e5.4) 0.03
468 4.79 (2.95e7.79) <0.001
96 1.95 (1.16e3.27) NR
1038 1.25 (1.00e1.55) 0.048
1038 1.24 (1.02e1.50) 0.027
ard ratio; MVA, multivariate analysis; NR, not reported; TNBC, triple-negative breast
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(>20 mm vs 20 mm) to be a signiﬁcant, independent factor
associated with survival by multivariate analysis (HR 1.240; 95% CI,
1.02e1.50; P ¼ 0.027; Table 3) [26]. Our evaluation criteria did not
return any other strongly supportive evidence in the metastatic
setting, and 1 recent study speciﬁcally stated that primary tumour
size was not prognostic for disease recurrence in patients with
nonmetastatic disease [58].
Discussion
In this literature analysis, the highest level of evidence (large
clinical trial) was available to support the following factors being
associated with aggressive MBC: visceral metastases, number of
metastatic sites, disease-free interval, presence of CTCs, triple-
negative disease, and tumour grade [17,21,28,33,47,49,53,57]. Only
retrospective reviews were available to support brain metastases,
HER2 positivity, and tumour size as markers of aggressive disease
[25,26,29]. However, in the case of HER2 positivity, this lack of
highest-level evidence is likely due to current trial designs, which
understandably provide different treatments for patients with
HER2þ disease and HER2 disease. Although the absence of clin-
ical trial data for brain metastases was somewhat unexpected, the
lack of data on tumour size may have been less so, as this factor is
often thought of as a marker of prognosis for early-stage breast
cancer.
Even though the underlying mechanisms are not always known,
some of these identiﬁed factors have shown a possible contribution
to rapid disease progression or resistance to treatment. Therefore,
understanding prognosis and treatment options for these patient
types is of particular importance in patient management.
This review focused on clinical and biological factors associated
with inherent disease aggressiveness. As such, we did not discuss a
handful of identiﬁed patient-related factors that are thought to be
important clinically, including age, performance status, comorbid-
ities, and race. Also beyond the scope of this review were more
recently identiﬁed factors, such as genetic mutations, markers of
inﬂammation, and receptor concordance between the primary
tumour and metastatic sites.
Although in this review histological subtyping was prioritized
ahead of molecular subtyping as a prognostic tool due its current
clinical use, there is evidence that molecular subtypes are also
related to outcomes, including survival [37,40]. Molecular analysis
allows for a more nuanced examination of tumour biology than
histological subtyping. The Cancer Genome Atlas Network charac-
terized the molecular subtypes by examining gene expression
proﬁles, somatic mutations, structural rearrangements, copy
number alterations, and epigenetic events [6]. The study described
variability between and within molecular subtypes; however, it
was revealed that somatic mutations in just 3 genes (TP53, PIK3CA,
and GATA3) were present in >10% of all breast cancers. In addition, a
retrospective analysis (N ¼ 437) suggested that molecular subtyp-
ing demonstrated a potential beneﬁt over histological subtyping in
identifying speciﬁc subsets of patients that may be more vs less
likely to beneﬁt from speciﬁc treatments [37]. Future prospective
studies that evaluate the efﬁcacy of speciﬁc treatments on molec-
ularly deﬁned subtypes may further answer the question of the
added value provided by a molecular vs histological subtyping
approach.
Nuclear Ki-67 is a prognostic factor in early-stage breast cancer
[59]. Although it did not meet the criteria for inclusion in this
systematic review, studies have suggested that a high nuclear Ki-67
level in primary tumours may also predict poorer outcomes in
patients with MBC [60,61]. In one study, a signiﬁcant association
was observed between Ki-67 level and shorter time to progressionin patients (n ¼ 146) treated with aromatase inhibitors (HR 1.19,
P ¼ 0.041) [60]. A separate study of patients being treated with
endocrine therapy as ﬁrst-line treatment for ER-positive MBC
(n ¼ 241) characterized Ki-67 levels as low (<10%), intermediate
(10%e25%), or high (>25%) and found signiﬁcant associations of Ki-
67 with clinical beneﬁt rate, time to progression, and OS (P  0.001
for each) [61]. A recent retrospective study of 210 patients with
MBC demonstrated that low levels of Ki-67 in metastatic lesions
(mKi-67 20%) were signiﬁcantly associated with longer OS (me-
dian 25 vs 17 months; HR 0.69; P ¼ 0.01) [62]. More research is
needed to fully elucidate the biological implications of Ki-67 for
MBC treatment.
Another intriguing subject in understanding breast cancer
aggressiveness is the spectrum of somatic mutations that may
contribute to breast cancer pathogenesis and resistance to thera-
pies [63]. For example, alterations in the ESR1 gene may lead to
endocrine therapy resistance in hormone receptorepositive breast
cancer [64]. Such results should only be considered hypothesis-
generating at this point; however, future treatment paradigms
may eventually be inﬂuenced by deep genomic analysis. Each of
these recently identiﬁed factors is interesting, and continued
research will give ever more biological insight as to the contribu-
tion of each of these factors to disease progression.
Advances in the overall care of patients with MBC has led to
improved trial designs and the possibility that analyses of prog-
nostic factors can be accounted for in studies' statistical plans. Data
from such trials will contribute to a more comprehensive under-
standing of each patient's unique disease phenotype and accelerate
our ability to offer personalized treatment.
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